Detalles de la búsqueda
1.
Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.
Br J Haematol
; 169(2): 199-210, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25643589
2.
Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
Am J Hematol
; 89(8): 795-802, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24757092
3.
Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment.
Clin Immunol
; 149(1): 97-110, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23948613
4.
Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients.
Clin Cancer Res
; 20(3): 724-35, 2014 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24297862
5.
TNFR2 Expression on CD25(hi)FOXP3(+) T Cells Induced upon TCR Stimulation of CD4 T Cells Identifies Maximal Cytokine-Producing Effectors.
Front Immunol
; 4: 233, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23964278
6.
Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: implications for immunotherapy.
Cancers (Basel)
; 4(2): 581-600, 2012 Jun 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-24213326
Resultados
1 -
6
de 6
1
Próxima >
>>